Retatrutide — research catalogue reference

Retatrutide is a single-chain synthetic peptide (development code LY3437943) designed to act at three incretin and metabolic receptors — GLP-1, GIP and the glucagon receptor — rather than one. That multi-receptor design is the reason it is studied separately from single- and dual-agonist peptides.

It is an investigational compound. It has not been registered by the TGA and is supplied here only as a laboratory reference material for in-vitro work.

Peer-reviewed work on Retatrutide sits in the metabolic research literature and examines receptor binding and signalling behaviour across the three target receptors, plus metabolic endpoints in clinical trial settings run by the compound's developer.

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds glucagon-receptor activity on top of both, which is why it is described as a triple agonist in the literature.

Aussie Peptides does not publish product- or lot-specific preparation, storage or stability data. Base preparation, storage and disposal on the supplier safety data sheet (SDS) and your institution's standard operating procedures.

Where a vial label shows a lot number and a batch report has been published for that lot, it can be looked up on the verify page and recorded alongside your experimental data.

Materials on this site are supplied strictly for in-vitro laboratory research. They are not offered for human or veterinary use. A research-use label does not by itself determine regulatory status; see the compliance page for official TGA guidance.

Purchasers must be 18 or over and are responsible for handling, storing and disposing of research materials in line with their institution's requirements and applicable Australian law.

Nothing on this page is medical advice, a dosing protocol, or a claim of therapeutic benefit. It summarises what the published research literature investigates.